Overview

Treatment Regimens in Meibomian Gland Dysfunction

Status:
Active, not recruiting

Trial end date:
2022-10-21

Target enrollment:

Participant gender:

Summary

This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.

Phase:

Phase 4

Details

Lead Sponsor:

Tauber Eye Center

Treatments:

Lifitegrast